Literature DB >> 8018658

Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells.

W Zhang1, J Wojta, B R Binder.   

Abstract

Among other Chinese herb drugs, Panax notoginseng is used to treat cardiovascular diseases. To elucidate any possible effects of this drug on the hemostatic system in vitro, we analyzed the influence of one of its major active constituents on fibrinolytic parameters of cultured human umbilical vein endothelial cells (HUVECs). When confluent cultures of HUVECs (passages 2 to 3) were conditioned with purified notoginsenoside R1 (NR1), a dose- (0.01 to 100 micrograms NR1/mL) and time-dependent increase in tissue-type plasminogen activator (TPA) synthesis was observed, which was significant from 0.1 microgram NR1/mL and from 6 hours of incubation with 100 micrograms NR1/mL on. TPA antigen increased from 3.9 +/- 0.2 ng per 10(5) cells per 24 hours to 8.0 +/- 0.5 ng per 10(5) cells per 24 hours on addition of 100 micrograms NR1/mL. In contrast, no change in urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) antigen synthesis was seen. There was also no effect of NR1 on PAI-1 deposition in the extracellular matrix. As judged from fibrin autography and reverse fibrin autography, TPA activity and TPA-PAI-1 complexes reached a maximal stimulation of more than threefold and twofold, respectively, at a concentration of 100 micrograms NR1/mL in conditioned media. On the contrary, NR1 induced a more than fivefold decrease in PAI-1 activity at the same concentration of NR1 in conditioned media. On Northern blot analysis of RNA obtained from NR1-stimulated and control HUVECs, NR1 induced a significant increase in TPA mRNA (192% of control value at 100 micrograms NR1/mL) while PAI-1 mRNA remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018658     DOI: 10.1161/01.atv.14.7.1040

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  7 in total

1.  Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457.

Authors:  Ying Yang; Peng Xi; Yuan Xie; Cuimei Zhao; Jiahong Xu; Jinfa Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Exploring mechanisms of Panax notoginseng saponins in treating coronary heart disease by integrating gene interaction network and functional enrichment analysis.

Authors:  Gui Yu; Jie Wang
Journal:  Chin J Integr Med       Date:  2016-05-16       Impact factor: 1.978

3.  A multivariate analysis on the comparison of raw notoginseng (Sanqi) and its granule products by thin-layer chromatography and ultra-performance liquid chromatography.

Authors:  Xian Zhou; Valentina Razmovski-Naumovski; Kelvin Chan
Journal:  Chin Med       Date:  2015-06-06       Impact factor: 5.455

Review 4.  Panax notoginseng Saponins for Treating Coronary Artery Disease: A Functional and Mechanistic Overview.

Authors:  Lian Duan; Xingjiang Xiong; Junyuan Hu; Yongmei Liu; Jun Li; Jie Wang
Journal:  Front Pharmacol       Date:  2017-10-17       Impact factor: 5.810

Review 5.  Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases.

Authors:  Hai Liu; Jianqiong Yang; Wanqing Yang; Shaonan Hu; Yali Wu; Bo Zhao; Haiyan Hu; Shouying Du
Journal:  Drug Des Devel Ther       Date:  2020-02-07       Impact factor: 4.162

6.  Effects of Korean Red Ginseng extract on tissue plasminogen activator and plasminogen activator inhibitor-1 expression in cultured rat primary astrocytes.

Authors:  Hyun Myung Ko; So Hyun Joo; Pitna Kim; Jin Hee Park; Hee Jin Kim; Geon Ho Bahn; Hahn Young Kim; Jongmin Lee; Seol-Heui Han; Chan Young Shin; Seung Hwa Park
Journal:  J Ginseng Res       Date:  2013-10       Impact factor: 6.060

Review 7.  Therapeutic Potential and Cellular Mechanisms of Panax Notoginseng on Prevention of Aging and Cell Senescence-Associated Diseases.

Authors:  Haiping Zhao; Ziping Han; Guangwen Li; Sijia Zhang; Yumin Luo
Journal:  Aging Dis       Date:  2017-12-01       Impact factor: 6.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.